

**FAX this completed form to (877) 386-4695**

**OR Mail requests to: Envolve Pharmacy Solutions PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720**

I. PROVIDER INFORMATION		II. MEMBER INFORMATION	
Prescriber Name:		Member Name:	
Prescriber Specialty:		Identification #:	
Office Contact Name:		Group #:	
Group Name:		Date of Birth:	
Fax #:		Medication Allergies:	
Phone #:			
III. DRUG INFORMATION (One drug request per form)			
Drug name and strength:	Dosage Interval (sig):	Qty. per Day:	
IV. REQUIRED DOCUMENTATION (Detailed medical record documentation demonstrating evidence for each item must be submitted with prior authorization request)			
Specify diagnosis & diagnosis code relevant to this request:		Dx/Dx Code: _____	
Does the member have a history of contraindication to the prescribed medication?		<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>	
<b>Requests for all non-preferred medications:</b> Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Migraine Prevention Agents? Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred medications in this class.		<input type="checkbox"/> Yes <i>Submit documentation of previous trials/failures, contraindications, and/or intolerances or current use.</i> <input type="checkbox"/> No	
<input type="checkbox"/> If not prescribed by one of the following specialist neurologist or headache specialist (certified in headache medicine but the United Council for Neurological Subspecialties (UCNS)), please indicate a specialist consulted: _____ <input type="checkbox"/> The requested medication will NOT be use concurrently with another with another Migraine Prevention Agent or small molecule CGRP receptor agonist (gepant) (e.g., Aimovig, Ajovy, Emgality, Vyepti or Nurtec, Ubrovelvy) <input type="checkbox"/> If requesting for daily quantity exceeding daily limit (Refer to <a href="https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx">https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/Quantity-Limits-and-Daily-Dose-Limits.aspx</a> ), please provide supporting information: _____			
SUBMIT MEDICAL RECORD INFORMATION FOR EACH APPLICABLE ITEM.			
MIGRAINE PREVENTION:			
<input type="checkbox"/> Member has a diagnosis of migraine with or without aura confirmed according to the current International Headache Society Classification of Headache Disorder <input type="checkbox"/> Average number of migraine and headache days per month at baseline _____ <input type="checkbox"/> Member has 4 or more migraine days per month over the past 3 months <input type="checkbox"/> Documented history of therapeutic failure, contraindication or intolerance to at least 2 of the following: (medication, start date and end date) <input type="checkbox"/> Beta-Blocker (e.g. metoprolol, propranolol, timolol): _____ <input type="checkbox"/> Antidepressant (e.g. amitriptyline, venlafaxine): _____ <input type="checkbox"/> Anticonvulsant (e.g. topiramate, valproic acid, divalproex): _____			
MIGRAINE PREVENTION RENEWAL REQUESTS:			
<input type="checkbox"/> Member has had a reduction in the average number of migraine and headache days per month from baseline _____ <input type="checkbox"/> Member has experienced a decrease in severity or duration of migraines from baseline evidenced by: _____			

**EPISODIC CLUSTER HEADACHE:**

- ☐ Member has a diagnosis of episodic cluster headache confirmed according to the current International Headache Society Classification of Headache Disorder
- ☐ Documented history of therapeutic failure, contraindication or intolerance to at least 1 preventative medication recommended by consensus guidelines for episodic cluster headache (American Academy of Neurology, American Academy of Family Physicians, American Headache Society): (medication, start date and end date)
  - ☐ Verapamil:\_\_\_\_\_
  - ☐ Topiramate:\_\_\_\_\_

**EPISODIC CLUSTER HEADACHE RENEWAL REQUESTS:**

- ☐ Member has experienced a positive clinical response as evident by a reduction in cluster headache frequency from baseline\_\_\_\_\_

**IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMATION :**

Appropriate clinical information to support the request on the basis of medical necessity must be submitted.	Provider Signature:	Date:
--------------------------------------------------------------------------------------------------------------	---------------------	-------

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours.  
Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)